The Hidden Costs of Immunotherapy — The Lines Nobody Budgets For

Four things, every cycle or every few cycles: day-care administration, interval blood tests, response-assessment scans, and the treatment of any immune-related side effect. Together these typically add roughly 30-40% on top of the drug line across a year. All figures on this page are indicative, as of August 2026.

Families are usually quoted one number — the price of a cycle — and multiply it by the number of cycles. That is where budgets fail. Immunotherapy is a schedule of infusions with a monitoring programme attached, and the monitoring does not stop while treatment continues. Here is the whole bill, line by line.

Immunotherapy is administered as day care at CION centres — you come in, are treated, and go home the same day. Response-assessment PET-CT is coordinated at partner imaging centres, not owned by CION, and those scans are billed by the imaging centre directly.

Three, mostly. Repeat imaging, because reassessment scans recur every two to three months and are billed by the imaging centre. The management of an immune-related side effect, because it is unpredictable and can involve an admission. And the non-medical costs — travel, leave from work, and a caretaker's lost income.

• Repeat imaging, not one scan. A baseline scan plus a reassessment every two to three months means several scans across a year. Each is a separate bill from the imaging centre.
• A steroid course brings its own costs. Managing a moderate immune reaction usually means high-dose steroids, extra blood tests, and medicines to protect the stomach and bones while you are on them.
• An unplanned admission. Immune colitis, pneumonitis, hepatitis, myocarditis or a hormone crisis can need inpatient care. This is the single largest unbudgeted item on most immunotherapy bills.
• Delays that repeat the workup. When a cycle is postponed, the pre-cycle bloods are usually repeated. Two or three delays across a year add up quietly.
• Consultations outside the plan. An urgent review for a new symptom is a consultation, and sometimes a scan, that no estimate anticipated.
• The biomarker test itself. PD-L1, MSI or a genomic panel is usually paid for before immunotherapy is even confirmed as an option for you.
• Travel every two to three weeks. Families coming in from districts pay for the journey on every cycle, and often for a night's stay, for as long as treatment continues.
• Lost income on both sides. The patient's earnings and the caretaker's leave are real household costs that appear on no hospital estimate at all.

One question surfaces most of this in a single sitting: "apart from the drug, what else will we be billed for in a normal month on this treatment?" Ask it before the first cycle, and ask for the answer written down and dated.

Build the number instead of guessing it. Take the per-cycle drug cost, multiply by the cycles planned before the first response assessment, then add an uplift for day care, monitoring and scans. Model a straightforward year and a complicated year separately. Both are realistic. Indicative, as of August 2026.

The fourth row is the one families find hardest to plan for and the one most estimates never mention. Immunotherapy does not help everyone, and the first response assessment is where that becomes visible. A budget built only for the good scenario leaves a family with no room to make the next decision calmly. Build for the point where the treatment is reviewed — not for a whole year at once.

Not starting is a real option, and a legitimate one. If the honest arithmetic says a family cannot sustain a course, that deserves a conversation with the treating oncologist before the first cycle, not a quiet default halfway through. There is usually more than one reasonable path, and the tumour board can be asked to look at all of them.

Most of them, partly, and none of them by cutting cycles. Scheme cover, a correctly filed insurance pre-authorisation, an itemised written estimate before you start, doing routine bloods closer to home, and knowing where the first decision point sits will move the total more than hunting for a cheaper vial does.

• Check scheme cover before the first cycle. Under Telangana's Aarogyasri scheme, certain immunotherapy packages may be covered up to scheme-defined ceilings. Empanelment, package contents and ceilings change — confirm the current position with the treating hospital's scheme desk. See CM Relief Fund, PM Fund and NGO Support for Immunotherapy for the routes that sit alongside it.
• File the insurance pre-authorisation properly the first time. A large share of refusals are documentation problems rather than policy exclusions. Ask the hospital's insurance desk exactly which reports the insurer wants, and check sub-limits and how your policy defines day care.
• Ask for an itemised, dated estimate. Drug, day care, monitoring bloods and scans on separate lines — not one lump figure. Anything undated is not an estimate, it is a memory.
• Budget to the first decision point, not to a year. Ask how many cycles are planned before the first response assessment, and fund that stretch properly. The next stretch is a separate decision.
• Ask whether a lower-cost approved version of the molecule exists. For one molecule a domestically manufactured biosimilar has been available in India since January 2026; for others it has not. Whether one applies to your prescription is a question for your oncologist and the hospital pharmacy — never for a reseller.
• Ask whether routine bloods can be done closer to home. For families travelling in from districts, moving interval blood tests to a local lab that the treating team accepts can cut several trips a year.
• Ask whether a clinical trial fits your diagnosis. Some trials supply treatment at no drug cost. Eligibility is strict and enrolment is never promised, but it costs nothing to ask — see Immunotherapy Through a Clinical Trial: The Free Access Route.
• Get the cost of a complication priced in advance. Ask what an outpatient steroid course adds and what a short admission adds, and hold both numbers before you need either.

Five questions settle almost everything. What the full monthly bill looks like, how many cycles before the first assessment, what a side effect would add, where the scheme and insurance position stands, and what the honest alternative is if the family cannot sustain it. Ask them together, and ask for the answers in writing.

1. 1

   "What will we be billed for in a normal month, apart from the drug?"

   Day care, bloods, review consultations and scans listed separately, with the date the estimate was prepared.

2. 2

   "How many cycles before we know whether this is working?"

   This is the number a family can actually budget for. Fund that stretch, then reassess the money along with the scans.

3. 3

   "If an immune side effect needs treating, what does that add?"

   Ask for both versions — managed as an outpatient, and managed as an admission. The second is the one that derails budgets.

4. 4

   "Where do we stand on Aarogyasri and on my policy?"

   Ask the scheme desk and the insurance desk, not the treating doctor. Get the current position, in writing, before cycle one.

5. 5

   "If we cannot sustain this, what is the honest alternative?"

   There is usually more than one reasonable path, including not starting. Say plainly that money is the constraint — it is a legitimate reason and a common one.

If money is the deciding factor, say so out loud. A treating team can plan around a stated constraint. It cannot plan around cycles that are quietly delayed or skipped, and delaying cycles to save money can change how the treatment works. That conversation belongs in the consulting room, before the first infusion.

Seeing the full cost is the first step; deciding what to do about it is the second. These companion pages cover the three questions families ask immediately afterwards — where funding can come from, whether a trial is an option, and whether the spend is worth it at all.

• CM Relief Fund, PM Fund and NGO Support for Immunotherapy — the funding routes that exist outside insurance, what each realistically covers, and how families apply.
• Immunotherapy Through a Clinical Trial: The Free Access Route — how trials work, what they do and do not pay for, and why eligibility is strict.
• Is Immunotherapy Worth the Money? A Framework for Deciding — a way to weigh the full cost against what the treatment is likely to offer in your situation.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring and cost counselling fit together as one pathway.

Decisions for Healing, Not Billing

We put the whole number in front of you first, including the lines most estimates leave out, so the decision stays with your family.